Comparative efficacy of oral dexamethasone versus
|
|
- Gwendoline Fields
- 5 years ago
- Views:
Transcription
1 Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma Faiqa Qureshi, MD, Arno Zaritsky, MD, and Michael P. Poirier, MD From the Department of Pediatrics and the Division of Pediatric Emergency Medicine, Children s Hospital of The Kings Daughters and Eastern Virginia Medical School, Norfolk, Virginia. Submitted for publication Oct 2, 2000; revision received Dec 19, 2000; accepted Feb 2, Reprint requests: Faiqa Qureshi, MD, Division of Pediatric Emergency Medicine, Children s Hospital of The King s Daughters, 601 Children s Ln, Norfolk, VA Copyright 2001 by Mosby, Inc /2001/$ /21/ doi: /mpd ORIGINAL ARTICLES Objective: The objective was to determine whether 2 days of oral dexamethasone (DEX) is more effective than 5 days of oral prednisone/prednisolone (PRED) in improving symptoms and preventing relapse in children with acute asthma. Study design: This was a prospective randomized trial of children (2 to 18 years old) who presented to the emergency department with acute asthma. PRED 2 mg/kg, maximum 60 mg (odd days) or DEX 0.6 mg/kg, maximum 16 mg (even days) was used. At discharge children in the PRED group were prescribed 4 daily doses (1 mg/kg/d, maximum 60 mg); children in the DEX group received a prepackaged dose (0.6 mg/kg, maximum 16 mg) to take the next day. The primary outcome was relapse within 10 days. Results: When DEX was compared with PRED, relapse rates (7.4% of 272 vs 6.9% of 261), hospitalization rates from the emergency department (11% vs 12%) or after relapse (20% vs 17%), and symptom persistence at 10 days (22% vs 21%) were similar. In the PRED group more children were excluded for vomiting in the emergency department (3% vs 0.3%; P =.008), more parents were noncompliant (4% vs 0.4%; P =.004), and more children missed 2 days of school (19.5% vs 13.2%; P =.05). Conclusion: In children with acute asthma, 2 doses of dexamethasone provide similar efficacy with improved compliance and fewer side effects than 5 doses of prednisone. (J Pediatr 2001;139:20-6) Asthma accounts for >1.8 million emergency department visits annually, and children account for approximately half of these visits. 1 Suppression and reversal of inflammation is the cornerstone for managing acute symptoms and preventing relapse. Guidelines emphasize the use of a short course of corticosteroids at discharge from the ED to decrease relapse. 2 A common practice is to prescribe a 4- to 5-day course of prednisone/prednisolone to children with asthma exacerbations. See editorial, p 3. Despite receiving prescriptions for corticosteroids, 5% to 25% of patients discharged from the ED will have relapse within 3 weeks Admission rates for patients with relapse vary from 50% 3 to 83% 10 and may be affected by patient compliance. Even with short-term medication regimens, 7% to 28% of patients never fill their prescriptions Poor palatability of the medication and a treatment period of several days may further reduce patient compliance. Dexamethasone is a long-acting corticosteroid that is well absorbed and has been used safely in children with croup. Our hypothesis was that a 2- day course of DEX dispensed from the ED would be well tolerated and superior to a prescribed 5-day course of PRED in improving symptoms and preventing relapse in the 10 days after an acute asthma exacerbation. DEX Oral dexamethasone ED Emergency department PEFR Peak expiratory flow rate PRED Oral prednisone/prednisolone METHODS Study Population The study group consisted of children 2 to 18 years old with a known history of asthma (2 or more episodes of wheezing treated with β-adrenergic agonists ± steroids) who presented to the pediatric ED with an acute exacerbation, defined as worsening of their asthmatic symptoms or increased difficulty in breathing with worsening of their peak expiratory flow rates. Children <2 years old were not enrolled to avoid including patients with bronchiolitis. Children were considered for the study if they required at least 2 albuterol nebulizer treatments in the ED. Informed consent was obtained from the parent or legal guardian, and assent was obtained from the patient, if appropriate.
2 THE JOURNAL OF PEDIATRICS VOLUME 139, NUMBER 1 QURESHI, ZARITSKY, AND POIRIER Children were excluded for any of the following reasons: reported use of oral corticosteroids in the 4 weeks before the current episode, history of intubation, varicella exposure in the preceding 3 weeks, concurrent stridor, possible presence of an intrathoracic foreign body, chronic respiratory disease (eg, cystic fibrosis), cardiac disease, or the need for immediate airway intervention. Study Design This randomized, prospective, clinical trial was approved by the Institutional Review Board of the Eastern Virginia Medical School. The study took place between November 1998 and September 1999 at the ED of a 168-bed tertiary care urban pediatric hospital. To limit potential investigator bias, the ED nursing staff classified the initial severity of an acute asthma exacerbation. Each child s exacerbation was classified as mild, moderate, or severe based either on the percentage of a child s predicted PEFR or an asthma score. Our asthma scoring system (modified from one published by the National Institutes of Health) 16 rates the severity of an asthma episode according to signs and symptoms and is used to evaluate the degree of respiratory distress in patients who are too young or uncooperative with performing reliable pulmonary function tests. It was validated in 2 previous studies of children with acute asthma. 17,18 Each patient s asthma episode was classified as mild if the PEFR was >70% of the predicted value or the asthma score was 5 to 7, moderate if the PEFR was 50% to 70% of the predicted value or the asthma score was 8 to 11, or severe if the PEFR was <50% of the predicted value or the asthma score was 12 to 15. PEFR was used to determine asthma severity if the child s effort was considered to be reliable and reproducible and could be obtained throughout the study period; otherwise, the asthma score was used to classify the severity of the exacerbation. The predicted PEFR was determined from normative data for patients of the same height, sex, and race. 19 All children were treated according to our standard ED asthma treatment protocol. Children received the first 3 albuterol nebulizations at 20-minute intervals (2.5 mg if weight <20 kg or 5 mg if weight >20 kg), and subsequent doses were given as ordered by the physician. Ipatropium bromide (0.5 mg) was added to 2 or 3 of the initial albuterol nebulizations depending on asthma severity. Oral corticosteroids were given with the second dose of nebulized albuterol. Oxygen was administered to maintain the patient s oxygen saturation (measured by pulse oximeter) 94%. Children who needed a second dose of albuterol were approached for enrollment in the study. On odd enrollment days children received oral PRED, and on even enrollment days children received oral DEX. Children in the PRED group received 2 mg/kg; maximum 60 mg of liquid prednisolone (Prelone 15 mg/5 cc) or prednisone USP 10-mg or 20- mg tablets (dose rounded to the nearest 5 mg). The choice between liquid or tablet was based on parental and child preference. If the child vomited the liquid medication, he or she was strongly urged to consider crushed tablets mixed in applesauce or chocolate/vanilla pudding for the subsequent dose. Children in the DEX group received 0.6 mg/kg; maximum 16 mg of dexamethasone USP 4-mg tablets (dose rounded to the nearest 2 mg) given as intact tablets or crushed and mixed in applesauce or chocolate pudding. The dose of either medication was readministered if the patient vomited within 30 minutes of taking it. Those who vomited 2 doses of the steroid were excluded from the study. The child s current asthma medications were recorded. Pulse and respiratory rates, pulse oximeter readings, PEFR, and asthma score were recorded before the first nebulizer treatment and after each subsequent treatment. The total number of nebulizer treatments, patient disposition, and medications at discharge were recorded. A decision to admit or discharge the child was made by the attending physician based on relief of symptoms, objective improvement in clinical asthma score, PEFR, or both, and the ability to maintain oxygen saturations 94% on room air. Only children who were discharged from the ED with corticosteroids were included in the final analysis. At discharge children in the PRED group were given a prescription for 4 daily doses of prednisone/prednisolone (1 mg/kg/dose; maximum 60 mg/d). Children in the DEX group received a premeasured dose of dexamethasone (0.6 mg/kg; maximum 16 mg) to take at home the next day. Albuterol inhalations were recommended on a 4- to 6-hour basis for the first 2 days after discharge, then as needed. No other asthma medications were to be used during the next 10 days. The primary outcome measure was the rate of relapse, defined as an unscheduled visit to a medical facility resulting from the patient s or parent s perception of persistent, worsening, or recurrent asthma symptoms in the 10 days after discharge from the ED. Secondary outcome measures were the rate of hospitalization (both initially from the ED and after relapse), frequency of vomiting, reported medication compliance, persistence of symptoms, and school or workdays missed. A research assistant contacted each patient s family 11 to 14 days after the patient was discharged from the ED to obtain follow-up data. Statistical Analysis Assuming a baseline relapse rate of 12% and accepting an α of 0.05 and a β of 0.8, a sample size of 250 per group was needed to detect an absolute difference in relapse rate of 5% between the groups. 21
3 QURESHI, ZARITSKY, AND POIRIER THE JOURNAL OF PEDIATRICS JULY 2001 variables were non-normally distributed, and Cramer s V test of association for 2 J tables when J > 2 and data were nominal. All proportions were tested with the 2-sample test of proportions. Logistic regression was used to determine whether there was a relation between study group and relapse. Analysis was conducted with STATA software version 6.0. RESULTS Figure. Patient enrollment data showing number of eligible patients, number of patients who were not enrolled (and reason they were not included), and number of patients who completed this study. Fifteen percent of enrolled patients were subsequently excluded for reasons noted in lower right box. Table I. Baseline demographic and clinical data The 2 groups were compared by appropriate tests of association. We used Pearson s χ 2 test for dichotomous and ordinal variables, the Student t test for DEX (n = 272) PRED (n = 261) P value Sex.99 Male (%) 178 (65) 171 (66) Female (%) 94 (35) 90 (34) Race.07 White (%) 44 (16) 26 (10) Black (%) 219 (81) 229 (88) Other (%) 9 (3) 6 (2) Age (y) 6 (5,7) 7 (6,7).06 Weight (kg) 23.2 (21.7, 26.1) 25.9 (24.5, 29).05 Heart rate 124 (119, 126) 119 (116, 122).20 Respiratory rate 32 (30, 32) 30 (28, 30).07 Pulse oximeter saturation 96 (96, 97) 96 (96, 97).71 Previous medications β-agonist (inhaled) (%) 221 (81) 218 (84).54 β-agonist (oral) (%) 10 (4) 4 (2).18 Inhaled steroids (%) 52 (19) 36 (14).07 Other medications (%)* 21 (8) 22 (8).76 Initial asthma severity.92 Mild (%) 59 (22) 60 (23) Moderate (%) 153 (56) 146 (56) Severe (%) 60 (22) 55 (22) *Cromolyn, antihistamine, decongestant. Demographic comparisons with the number of children (percentage) shown. Continuous baseline characteristics are presented as median (95% CI). There were no significant differences in any baseline parameter between groups. equality of means when continuous variables were normally distributed, the Wilcoxon Rank Sum test for equality of medians when continuous Patient enrollment data are shown in the Figure. Patients could be enrolled more than once provided they had not used oral corticosteroids in the 4 weeks before the current episode. Approximately 8% of patients were included more than once. Of the 1231 eligible children, 628 were enrolled and 533 (272 in the DEX group and 261 in the PRED group) completed the study. As shown in the Figure, significantly more enrolled children were excluded for vomiting in the PRED group than in the DEX group (3% vs 0.3%; P =.008). The 2 groups were similar in demographic and baseline clinical characteristics, including initial asthma severity (Table I). There were no significant differences between groups in the parents reported use of inhaled or oral β-adrenergic agonists and inhaled steroids in the 24 hours before the ED visit (Table I). PEFR was performed on 185 (35%) children. Of these, only 96 children (18% of total; 49 in the DEX group and 47 in the PRED group) had PEFR data that were considered sufficiently reliable to classify initial severity of asthma. There was no difference between groups in the total number of nebulizer treatments (albuterol ± ipratropium) given in the ED, the total time spent in the ED, or asthma severity at discharge (Table II). There was no significant difference in relapse rates between the 2 groups (DEX 7.4%; PRED 6.9%; odds ratio 1.08; 95% CI 0.55 to 2.08; P =.84) 22
4 THE JOURNAL OF PEDIATRICS VOLUME 139, NUMBER 1 QURESHI, ZARITSKY, AND POIRIER (Table III). Of those who relapsed, there was no difference in the rate of subsequent admission. An intentionto-treat analysis of relapse rates, assuming that the children who were excluded for vomiting and those who were lost to follow-up all had relapse, favored the DEX group, but the difference was not significant (DEX 24 [8.7%] of 276; PRED 38 [13.5%] of 281; odds ratio 0.61; 95% CI 0.35 to 1.05; P =.07). When stratified by initial asthma severity, the relapse rate was similar between groups. Most relapses occurred in the first 3 days after ED discharge, with the greatest number occurring on day 2 (8 in the DEX group and 6 in the PRED group). There was no significant association between the time to relapse and the type of steroid administered. A significantly greater number of children in the PRED group missed 2 or more days of school, and more parents in the PRED group reported missing at least 1 day of work. More children reportedly vomited the PRED at home, and significantly more parents in the PRED group reported not giving their child the medication (because the prescription was not filled). This study was designed to compare current outpatient prescribed steroid therapy versus DEX dispensed from the ED. Even though 4% of the parents in the PRED group reported they did not fill the prescription, only 1 of these patients was among the 18 children who had relapse. In a similar fashion, only 1 child in the DEX group who relapsed did not get the steroid. If both these patients are excluded, there is no significant change in the comparative relapse rates between groups. There was no significant difference between the groups in the prevalence of persistent symptoms (cough, wheeze, chest tightness, night awakening, difficulty in maintaining daily activity) at the time of follow-up (Table III). Eighty-nine percent (243) of parents in the DEX group believed that the Table II. Clinical course in the emergency department DEX and PRED were comparable in efficacy and that the 2-day regimen of DEX, especially when dispensed from the ED, was much more convenient. Five parents believed that the DEX was not as effective as PRED, and 4 others reported that their child had been more irritable while taking the DEX. The remaining 20 dissatisfied parents in the DEX group had children who had relapsed. DISCUSSION This prospective, randomized, clinical trial found that the relapse rate in DEX (n = 272) PRED (n = 261) P value No. of nebulizers in ED 3 (3, 3) 3 (3, 3).30 Time in ED (min) 140 (130, 147) 125 (120, 132).09 Asthma severity at discharge Mild (%) 262 (96) 255 (98).35 Moderate (%) 10 (4) 6 (2) Data are shown as median (95% CI) or number of children (percentage) within outcome groups. There was no significant difference between groups in any parameter. Table III. Outcome data DEX PRED (n = 272) (n = 261) P value Primary outcome Relapse rate (%) 20 (7.4) 18 (6.9).84 Secondary outcomes Admit after relapse (%) 4 (20) 3 (17).81 Medication not given (%) 1 (0.4) 10 (4).004 Medication vomited at home (%) 6 (2) 11 (4).17 Missed 2 school days (%) 36 (13.2) 51 (19.5).05 Parent missed work (%) 44 (16.2) 59 (22.6).06 Persistent symptoms (by history) Cough (%) 57 (21.3) 48 (18.7).38 Wheeze (%) 32 (12.0) 30 (11.7).72 Tightness of chest (%) 11 (4.1) 11 (4.3) 1.0 Night awakening (%) 13 (4.9) 16 (6.2).61 Difficulty maintaining daily activity (%) 14 (5.2) 18 (7.0).33 Summary of outcomes 10 days after ED visit. Data show number of children (percentage) in each outcome group. children with acute asthma was not different when 2 doses of oral DEX (dispensed in the ED) were compared with 5 doses of oral PRED (1 dispensed in the ED and 4 prescribed home doses). There also was no difference in symptom improvement or the rate of hospitalization. Because corticosteroids improve pulmonary function, reduce the rate of hospitalization, and decrease the relapse rates in patients with acute asthma exacerbations, 5,6,20-25 PRED is recommended by the National Institutes of Health consensus panel for outpatient use after an asthma exacerbation. 2 These relatively short-acting 23
5 QURESHI, ZARITSKY, AND POIRIER THE JOURNAL OF PEDIATRICS JULY steroids have a biologic half-life of 12 to 36 hours, necessitating daily dosing of the drug, 26 usually for 4 to 5 days. Reasons for noncompliance with medications prescribed on discharge from the ED included lack of insurance, 12 insufficient funds, 13 parental noncompliance, 14 cost, 15 and medications prescribed for a course of several days. 27 Although parents knew that we would be monitoring their child, 10 (4%) parents in the PRED group admitted not giving the medication because they failed to fill the prescription. Noncompliance may have been higher, because there were frequent conflicting reports from different caretakers on whether the medicine was ever bought and how many doses were given. The 2 reasons given for not purchasing the PRED were insufficient funds (n = 6) and I forgot (n = 4). In the DEX group only 1 parent reported not giving their child the second dose of DEX. Children may vomit or refuse to swallow medication, especially if it is bitter or has to be given in large volumes. A 3% to 15% incidence of vomiting after oral PRED is taken has been reported. 10,28,29 Only those children who vomited both doses of steroids in the ED were used to calculate the incidence of vomiting, accounting for the low incidence compared with previous studies. In our study children given DEX tablets (crushed or whole) vomited less often than those given the PRED liquid or tablets, both in the ED and at home. Since this study was completed, we have used the parenteral formulation of DEX (dexamethasone sodium phosphate injection USP 10 mg/ml) mixed with flavored syrup for younger children, with very good patient acceptance. To improve compliance and decrease asthma relapse rates, several investigators have studied long-acting parenteral steroid preparations given at discharge from the ED. In a small study (17 patients), a single dose of intramuscular methylprednisolone acetate (80 mg) decreased relapse rates from 20% to 0% compared with a 10- day tapering dose of oral methylprednisolone. 11 In a larger study (56 patients), a larger dose of intramuscular methylprednisolone acetate (240 mg) reduced relapse rates from 31% to 7% compared with placebo. 3 A single dose of triamcinolone acetate (40 mg intramuscularly) produced a relapse rate equal to that of oral PRED (40 mg/d for 5 days), 4 and 1 dose of intramuscular DEX acetate produced similar improvement in symptoms compared with 5 days of oral PRED in 32 children discharged from a pediatric clinic. 27 Repository preparations of corticosteroids (the acetate form of methylprednisolone, triamcinolone, or dexamethasone), however, have a long duration of action (1 to 3 weeks), raising concern for prolonged adrenal suppression, especially if used in repeated doses. 30 Short-acting DEX phosphate (0.3 mg/kg) intramuscularly or 3 days of oral PRED was used in 42 children presenting to the ED with mild to moderate asthma. No child had a relapse or deterioration of symptoms during the subsequent 5 days. 31 Based on these studies, we hypothesized that patient compliance and tolerance would be improved with oral DEX rather than PRED in acute asthma. DEX is a potent, long-acting glucocorticoid with a biologic half-life of 36 to 72 hours. It is approximately 6 times more potent than PRED. 26 DEX is well absorbed orally; the relative oral bioavailability of DEX is 70% of that achieved by intramuscular administration. 32,33 Two doses of oral DEX at 0.6 mg/kg/dose should be pharmacologically equivalent to 5 days of oral PRED at 2 mg/kg on day 1, followed by 1 mg/kg on days 2 through 5. DEX at a dose of 0.6 mg/kg has been studied extensively in patients with croup without serious reported adverse effects The maximum intramuscular dose of DEX used in a previous study was 15 mg. 31 Because we were using 4-mg tablets of DEX, our maximal dose was 16 mg. All doses were rounded to within 15% of the desired dose of 0.6 mg/kg, which enabled the pharmacy to dispense the tablets in 2-mg ( 1 2 tablet) increments. Children in the DEX group did not have longer ED stays or an increase in the rate of hospitalization compared with children in the PRED group, suggesting that both steroids have similar time to onset of action. There was also no significant difference in the persistence of symptoms between groups in the 10 days after ED discharge. Although the study groups were well matched, there was a trend toward a higher rate of inhaled steroid use in the DEX group (19%) versus that in the PRED group (14%; Table I). Inhaled steroid use may be a surrogate marker for disease severity. However, in this study the relative risk of relapse in the children in the DEX group versus that in the children in the PRED group who were taking inhaled steroids was 1.21 (95% CI, 0.38, 3.84); thus there was no apparent effect of inhaled steroid use on the likelihood of relapse in either treatment group. Because the relapse rate was not different between groups, a 2-dose DEX regimen dispensed from the ED may be preferred because of improved compliance. Many of our patients do not understand the importance of antiinflammatory therapy. When combined with limited financial resources and inadequate follow-up with their primary care physician, compliance with any oral medication regimen can become a serious problem. Oral DEX is generically available, inexpensive (a 4-mg tablet costs 7 cents in our pharmacy vs 10 cents/ml for Prelone), and well tolerated orally. This study was not double-blind because DEX tablets were used versus PRED suspension or tablets. Potential investigator bias was limited, because the decision to return for further treatment after discharge from the ED was
6 THE JOURNAL OF PEDIATRICS VOLUME 139, NUMBER 1 QURESHI, ZARITSKY, AND POIRIER made by the parent without investigator input. The use of a third group of patients as an untreated control group would not have been ethical, because corticosteroid therapy has proven value in managing and preventing relapse in acute asthma. Further studies are required to determine whether a smaller dose of DEX is as effective as the 0.6 mg/kg dose and whether children with mild asthma exacerbations can be treated effectively with 1 dose of DEX given in the ED. The potential role of inhaled corticosteroids in the prevention of relapse is also not clearly defined. In conclusion, for the management of acute asthma, symptom improvement and the relapse rate were similar between children who received 2 doses of oral DEX or 5 doses of oral PRED. Advantages of DEX include fewer doses, reduced emesis, and a decrease in the number of school/work days missed. Patient compliance may also be improved by dispensing the second dose of medication from the ED. DEX is a practical alternative to PRED in the management of asthma exacerbations in children. We thank Drs Daniel Isaacman, Kathleen Doobinin, Theresa Guins, Michele Wadsworth, Jennifer Trainor, Alan Causey, Anita Maniktala, Craig Huang, and the emergency department staff for their help with patient enrollment. We also thank Bonnie Burke for her statistical support, Nermina Nakas for data entry, and Cindy Buckler for assistance with preparing this manuscript. REFERENCES 1. Centers for Disease Control and Prevention. Surveillance for asthma: United States MMWR Morb Mortal Wkly Rep 1998: National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 11 Pub. No : National Institutes of Health: Bethesda, MD: McNamara RM, Rubin JM. Intramuscular methylprednisolone acetate for the prevention of relapse in acute asthma. Ann Emerg Med 1993;22: Schuckman H, DeJulius DP, Blanda M, Gerson LW, DeJulius AJ, Rajaratnam M. Comparison of intramuscular triamcinolone and oral prednisone in the outpatient treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 1998;31: Harris JB, Weinberger MM, Nassif E, Smith G, Milavertz G, Stillerman A. Early intervention with short courses of prednisone to prevent progression of asthma in ambulatory patients incompletely responsive to bronchodilators. J Pediatr 1987;110: Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. N Engl J Med 1991;324: Emerman CL, Cydulka RK. Factors associated with relapse after emergency department treatment for acute asthma. Ann Emerg Med 1995;26: Verbeek PR, Geerts WH. Nontapering versus tapering prednisone in acute exacerbations of asthma: a pilot trial. J Emerg Med 1995;13: Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA 1999;281: Scarfone RJ, Loiselle JM, Wiley JF II, Decker JM, Henretig FM, Joffe MD. Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med 1995;26: Hoffman IB, Fiel SB. Oral vs repository corticosteroid therapy in acute asthma. Chest 1988;93: Thomas EJ, Burstin HR, O Neil AC, Orav EJ, Brennan TA. Patient noncompliance with medical advice after the emergency department visit. Ann Emerg Med 1996;27: Saunders CE. Patient compliance in filling prescriptions after discharge from the emergency department. Am J Emerg Med 1987;5: Matsui D, Joubert GI, Dykxhoorn S, Rieder MJ. Compliance with prescription filling in the pediatric emergency department. Arch Pediatr Adolesc Med 2000;154: Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994;87: Guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute: Bethesda, MD: Pub No Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998;339: Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med 1997;29: Hsu KHK, Jenkins DE, Hsi BP, Bourhofer E, Thompson V, Hsu FC, et al. Ventilatory functions of normal children and young adults Mexican- American, white, and black. I. Spirometry. J Pediatr 1979;95: Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma (Cochrane Review). The Cochrane Library 2000; Younger RE, Gerber PS, Herrod HG, Cohen RM, Crawford LV. Intravenous methylprednisolone efficacy in status asthmaticus of childhood. Pediatrics 1987;80: Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics 1990;86: Rowe BH, Keller JL, Oxman AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a meta-analysis. Am J Emerg Med 1992;10: Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993;92: Lin RY, Pesola GR, Bakalchuk L, Heyl GT, Dow AM, Tenenbaum C, et al. Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: a randomized controlled study. Ann Emerg Med 1999;33: Schimmer BP, Parker KL. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of the syntheses and actions of adrenocortical hormones. In: Martin J, Wonsiewicz PM, editors. Goodman & Gilman s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; p Gries DM, Moffitt DR, Pulos E, Carter ER. A single dose of intramus- 25
7 QURESHI, ZARITSKY, AND POIRIER THE JOURNAL OF PEDIATRICS JULY 2001 cularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children. J Pediatr 2000;136: Barnett PLG, Caputo GL, Baskin M, Kupperman N. Intravenous versus oral corticosteroids in the management of acute asthma in children. Ann Emerg Med 1997;29: Becker JM, Arora A, Scarfone RJ, Spector ND, Fontana-Penn ME, Gracely E, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol 1999;103: Weinberger M. Corticosteroids for exacerbations of asthma: problems and solutions [editorial]. J Pediatr 2000; 136: Klig JE, Hodge D III, Rutherford MW. Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone. J Asthma 1997;34: Loew D, Schuster O, Graul EH. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol 1986;30: Elliott CL, Read GF, Wallace EM. The pharmacokinetics of oral and intramuscular administration of dexamethasone in late pregnancy. Acta Obstet Gynecol Scand 1996;75: Geelhoed GC, Macdonald WBG. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatr Pulmonol 1995;20: Cruz MN, Stewart G, Rosenberg N. Use of dexamethasone in the outpatient management of acute laryngotracheitis. Pediatrics 1995;96: Johnson DW, Jacobson S, Edney PC, Hadfield P, Mundy ME, Schuh SA. Comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med 1998;339: Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup. Pediatr Emerg Care 1996;12: Klassen TP, Watters LK, Feldman ME, Sutcliffe T, Rowe PC. The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup. Pediatrics 1996;97: BOUND VOLUMES AVAILABLE TO SUBSCRIBERS Bound volumes of the 2001 issues of The Journal of Pediatrics are available to subscribers (only) from the Publisher, at a cost of $ for domestic, $ for Canadian, and $ for international subscribers, for Vol 138 (January-June) and Vol 139 (July-December), shipping charges included. Each bound volume contains subject and author indexes, and all advertising is removed. Copies are shipped within 60 days after publication of the last issue in the volume. The binding is durable buckram, with the Journal name, volume number, and year stamped in gold on the spine. Payment must accompany all orders. Contact Mosby, Subscription Customer Service, 6277 Sea Harbor Dr, Orlando, FL 32887; phone or Subscriptions must be in force to qualify. Bound volumes are not available in place of a regular Journal subscription. 26
Original Article. Kishore Kumar K 1, Sai Samrat K 2, Sony Reddy S 3 INTRODUCTION
Original Article A Comparative Study between Intramuscular and Oral Methylprednisolone Acetate in the Treatment of Asthma Exacerbation Following Discharge from the Hospital Kishore Kumar K 1, Sai Samrat
The New England Journal of Medicine EFFECT OF NEBULIZED IPRATROPIUM ON THE HOSPITALIZATION RATES OF CHILDREN WITH ASTHMA. Subjects
EFFECT OF NEBULIZED IPRATROPIUM ON THE HOSPITALIZATION RATES OF CHILDREN WITH FAIQA QURESHI, M.D., JOHN PESTIAN, PH.D., PARIS DAVIS, B.A., AND ARNO ZARITSKY, M.D. ABSTRACT Background Anticholinergic medications
Children suffering from asthma symptoms present
Original Article Single-Dose Oral Dexamethasone in the Emergency Management of Children With Exacerbations of Mild to Moderate Asthma Saleh Altamimi, MD, FRCP(C), FAAP, Glenn Robertson, MD, FRCP(C), UBC,
Oral versus intravenous corticosteroids in children hospitalized with asthma
Oral versus intravenous corticosteroids in children hospitalized with asthma Jack M. Becker, MD, a Anjali Arora, MD, b Richard J. Scarfone, MD, d Nancy D. Spector, MD, a Mary Elizabeth Fontana-Penn, MD,
Is Oral Dexamethasone Safe and Effective for Treating Asthma Exacerbations In Pediatric Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Oral Dexamethasone Safe and Effective
PEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze
Inclusion: Children experiencing acute asthma exacerbation 24 months to 18 years of age with a diagnosis of asthma Patients with a previous history of asthma (Consider differential diagnosis for infants
PAEDIATRIC ACUTE CARE GUIDELINE. Croup. This document should be read in conjunction with this DISCLAIMER
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Croup Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction
Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
Dex single dose Pred- 5 day course Mean Difference Mean Difference Mean 3.5. Weight 100.0% IV, Fixed, 95% CI [-1.97, 0.37] 100.
Question : In the child with asthma exacerbation in the ED should prednisolone/prednisone vs. dexamethasone be used to prevent hospitalization, decrease time in the ED or improve pulmonary function? Forest
The adult therapeutic substitution protocol follows:
Therapeutic Substitution of Albuterol - Implemented 1/15/2013 After years of evaluation, comparative studies have not consistently demonstrated clinical or safety advantages of levalbuterol over racemic
Is Dexamethasone an Effective Alternative to Oral Prednisone in the Treatment of Pediatric Asthma Exacerbations?
CLINICAL QUESTION REVIEW CQR is a recurring section in Hospital Pediatrics where authors start with a relevant clinical question, find and synthesize the recent literature and provide their best answer
Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis
Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis AUTHORS: Grant E. Keeney, MD, a Matthew P. Gray, MD, a Andrea K. Morrison, MD, MS, a Michael N. Levas, MD, a Elizabeth A. Kessler,
10/6/2014. Tommy s Story: An Overview of Asthma Mangement. Disclosure. Objectives for this talk.
Tommy s Story: An Overview of Asthma Mangement Clifton C. Lee, MD, FAAP, FHM Associate Professor of Pediatrics Chief, Pediatric Hospital Medicine Children s Hospital of Richmond at VCU Disclosure Obviously,
Nguyen Tien Dung A/Prof. PhD. MD Head of Pediatric Department - Bach Mai Hospital
Nguyen Tien Dung A/Prof. PhD. MD Head of Pediatric Department - Bach Mai Hospital A girl patient 11 years old admitted to Bach mai Hospital at 4h15, 12nd November because of difficult breathing She has
AT TRIAGE. Alberta Acute Childhood Asthma Pathway: Evidence based* recommendations For Emergency / Urgent Care
1 1 Should the child be placed into the Pathway? Asthma Clinical Score (PRAM) Inclusion Children 1 year and 18 years of age who present with wheezing and respiratory distress, and have been diagnosed by
Pediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research
Pediatric Respiratory Disease: A Model for the Future of Emergency Medicine Research Joseph J. Zorc, MD, MSCE Mark Fishman Professor, Department of Pediatrics Perelman School of Medicine, University of
Asthma Care in the Emergency Department Clinical Practice Guideline
Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely
In 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma
Acute Wheezing Emergencies: From Young to Old! Little Wheezers in the ED: Managing Acute Pediatric Asthma Talk Outline Case Delivery of bronchodilators Meter-dose inhalers and spacers Continuous nebulization
Oral Dexamethasone versus Oral Prednisolone in Acute Asthma: A New Randomized Controlled Trial and Updated Meta-analysis.
J O U R N A L C L U B Oral Dexamethasone versus Oral Prednisolone in Acute Asthma: A New Randomized Controlled Trial and Updated Meta-analysis. SOURCE CITATION: Paniagua N, Lopez R, Muñoz N, Tames M, Mojica
Steroid Storms: Controversies and Considerations in PEM
Steroid Storms: Controversies and Considerations in PEM Kimball Prentiss, MD, FAAP Division of Pediatric Emergency Medicine September 19, 2018 CCEM Conference, Northampton Objectives Develop an understanding
ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
Office of Evidence Based Practice Specific Care Question: Dexamethasone vs. Prednisone for a Pediatric Asthma Exacerbation
Specific Care Question : Is dexamethasone better than prednisolone/prednisone for a pediatric asthma exacerbation Question Originator: Jeff Michael, DO, FAAP Plain Language Summary from The Office of Evidence
Objectives. Case Presentation. Respiratory Emergencies
Respiratory Emergencies Objectives Describe how to assess airway and breathing, including interpreting information from the PAT and ABCDEs. Differentiate between respiratory distress, respiratory failure,
Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis. abstract REVIEW ARTICLE
REVIEW ARTICLE Dexamethasone for Acute Asthma Exacerbations in Children: A Meta-analysis AUTHORS: Grant E. Keeney, MD, a Matthew P. Gray, MD, a Andrea K. Morrison, MD, MS, a Michael N. Levas, MD, a Elizabeth
Diagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
Sample. Affix patient label within this box.
Instructions for completing orders Complete pages 1-3 for General Inpatient Orders. All pathway compatible orders (indicated by ) within the General Inpatient Orders will be followed automatically. Optional
Predicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
Comparison of Nebulized Budesonide with Intravenous Dexamethasone in the Treatment of Young Children Hospitalized with Acute Asthma
J Med Sci 2005;25(5):223-228 http://jms.ndmctsgh.edu.tw/2505223.pdf Copyright 2005 JMS Shu-Tse Lai, et al. Comparison of Nebulized Budesonide with Intravenous Dexamethasone in the Treatment of Young Children
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation
Peak Expiratory Flow Rate (PEFR) for ED Management of Acute Asthma Exacerbation PI: Brian Driver, MD Checklist Reviewed Inclusion and Exclusion Criteria Confirm pertinent exclusion criteria with PMP Engage
Croup (Laryngo-tracheo-bronchitis)
Croup (Laryngo-tracheo-bronchitis) 1a 2a 2b Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of
SYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
Medicine Dr. Kawa Lecture 4 - Treatment of asthma :
Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Avoiding allergens. Hyposensitization :Subcutaneous injections of inially very small, but gradually increasing doses of allergens (desensitization or
ASTHMA IN THE PEDIATRIC POPULATION
ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center
Asthma is global health problem in children,
Paediatrica Indonesiana VOLUME 52 July NUMBER 4 Original Article Efficacy of salbutamol-ipratropium bromide nebulization compared to salbutamol alone in children with mild to moderate asthma attacks Matahari
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing
What is the best way to treat recurrent wheeze in pre-school children?
What is the best way to treat recurrent wheeze in pre-school children? Miles Weinberger MD Professor of Pediatrics www.uihealthcare.com/allerpulm Lower airway obstruction Asthma vs bronchiolitis? Both
Dual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health.
Treatment of Acute Asthma Exacerbations in Adults in the Primary Care or Urgent Care Setting Clinical Practice Guideline MedStar Health Background: These guidelines are provided to assist physicians and
RESPIRATORY CARE Paper in Press. Published on August 26, 2014 as DOI: /respcare.02991
An Innovative Childhood Asthma Score Predicts the Need for Bronchodilator Nebulization in Children With Acute Asthma Independent of Auscultative Findings Arvid WA Kamps MD PhD, Nic JGM Veeger PhD, and
COPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol
RESEARCH ARTICLE Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol Amy Tyler, MD, MSCS, a,b Jillian M. Cotter, MD, a,b Angela
Secondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone
Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone Flávio Sano, MD, a Geny K. Cortez, MD, a Dirceu Solé, MD, b and Charles
Medications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
Oral Dexamethasone in the Treatment of Croup: 0.15 mglkg Versus 0.3 mglkg Versus 0.6 mglkg
Pediatric Pulmonology 20:362-368 (1995) Oral Dexamethasone in the Treatment of Croup: 0.15 mglkg Versus 0.3 mglkg Versus 0.6 mglkg G.C. Geelhoed, FRACP, and W.B.G. Macdonald, FRACP Summary. The objective
On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
Asthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
Lecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
Current Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial by Vikram Kumar, a P. Ramesh, a Rakesh Lodha, a R. M. Pandey,
Asthma Medications: Information for Children and Families. What You Need to Know about Medicines for Asthma
Page 1 of 8 PED-ALL-005-1992 Asthma Medications: Information for Children and Families What You Need to Know about Medicines for Asthma What Medicines Are used to Treat Asthma? There are two kinds of medicines:
Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
REVIEW AMINOPHYLLINE. Background
REVIEW AMINOPHYLLINE Background The current 13 th edition of the WHO Model Essential Medicines List (dated April 2003) includes aminophylline on the Complementary List. The listing is as shown below (together
Omalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
Significance. Asthma Definition. Focus on Asthma
Focus on Asthma (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Asthma Definition Chronic inflammatory disorder of airways Causes airway hyperresponsiveness
Early emergency department treatment of acute asthma with systemic corticosteroids (Review)
Early emergency department treatment of acute asthma with systemic corticosteroids (Review) Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G This is a reprint of a Cochrane review, prepared and maintained
SUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD WWW.chestjournal.org Background: Current reviews on the use of inhaled corticosteroids (ICS) for acute asthma underestimated
BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
Knowledge Translation and Emergency Medicine. Eddy Lang Jeremy Grimshaw Michael Brown
Knowledge Translation and Emergency Medicine Eddy Lang Jeremy Grimshaw Michael Brown Knowledge Translation The exchange, synthesis and application of research evidence within a complex system of relationships
Acute Laryngitis in Childhood
Acute Laryngitis in Childhood Hany Simon Junior Viral croup Definition The term croup syndrome characterizes a group of diseases with variable anatomic involvement and etiology, and is clinically manifested
Is There a Treatment for BPD?
Is There a Treatment for BPD? Amir Kugelman, Pediatric Pulmonary Unit and Department of Neonatology Bnai Zion Medical Center, Rappaport Faculty of Medicine Haifa, Israel Conflict of Interest Our study
ARTICLE. Effectiveness of Oral or Nebulized Dexamethasone for Children With Mild Croup
ARTICLE Effectiveness of Oral or Nebulized Dexamethasone for Children With Mild Croup Joseph W. Luria, MD; Javier A. Gonzalez-del-Rey, MD; Gregg A. DiGiulio, MD; Constance M. McAneney, MD; Jennifer J.
RESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
Emergency Department Protocol Initiative
Emergency Department Protocol Initiative ACUTE ASTHMA MANAGEMENT TOOLKIT March 2006 Provincial Emergency Services Project PHYSICIAN ORDER TEMPLATE FOR CTAS LEVEL 1 ASTHMA ADULT PEDIATRIC Date: Site: Arrival
Practical Approach to Managing Paediatric Asthma
Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis
How far are we from adhering to national asthma guidelines: The awareness factor
Egyptian Journal of Ear, Nose, Throat and Allied Sciences (2013) 14, 1 6 Egyptian Society of Ear, Nose, Throat and Allied Sciences Egyptian Journal of Ear, Nose, Throat and Allied Sciences www.ejentas.com
Portable Spirometry During Acute Exacerbations of Asthma in Children
Journal of Asthma, 46:122 125, 2009 Copyright C 2009 Informa Healthcare USA, Inc. ISSN: 0277-0903 print / 1532-4303 online DOI: 10.1080/02770900802460522 ORIGINAL ARTICLE Portable Spirometry During Acute
Nebulized budesonide to treat acute asthma in children
0021-7557/04/80-02/106 Jornal de Pediatria Copyright 2004 by Sociedade Brasileira de Pediatria ORIGINAL ARTICLE Nebulized budesonide to treat acute asthma in children Geórgia K. M. Milani 1, Nelson A.
Relevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic
Topic: Prehospital use of bromide paired with salbutamol as treatment for shortness of breath. Author: Lisa Henderson Clinical Scenario: Two primary care paramedics respond code 4 for a 55 year old male
SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
Early Studies. Then, the Meta-analysis. Recent Studies Al-Ansari. Recent Studies Luo University of Texas Health Science Center at San Antonio
Pediatrics Grand Rounds Objectives Review the available literature on the use of nebulized hypertonic saline in the treatment of acute viral bronchiolitis Review proposed mechanism(s) of action and safety
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Emergency Department Guideline. Asthma
Emergency Department Guideline Inclusion criteria: Patients 2 years old with: o Known history of asthma or wheezing responsive to bronchodilators presenting to the ED with cough, wheeze, shortness of breath,
Improving timeliness for acute asthma care for paediatric ED patients using a nurse driven intervention: an interrupted time series analysis.
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Emergency Medicine Faculty Publications Emergency Medicine 1-1-2016 Improving timeliness for acute
ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN
Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
1. What is delayed sequence intubation? Can it be used for severe Asthma exacerbation? 2. What about pregnancy and Asthma is so important?
Chapter 073 Asthma Episode Overview 1. 10 different causes of a wheeze. 2. List 8 risk factors for death from asthma 3. List 6 objective findings of severe asthma 4. 10 therapies for an acute severe asthma
Searching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
Meenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
Asthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
Evaluation of the Use of High-Dose Inhaled Corticosteroids for the Treatment of Acute Asthma
11 Inhaled Corticosteroids for Asthma Attacks ORIGINAL ARTICLE RAMR 2016;1:11-16 ISSN 1852-236X Evaluation of the Use of High-Dose Inhaled Corticosteroids for the Treatment of Acute Asthma Correspondence:
Corticosteroids for preventing relapse following acute exacerbations of asthma (Review)
Corticosteroids for preventing relapse following acute exacerbations of asthma (Review) Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G This is a reprint of a Cochrane review, prepared and maintained
A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup
The new england journal of medicine original article A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup Candice L. Bjornson, M.D., Terry P. Klassen, M.D., Janielee Williamson, R.N.,
Management of acute asthma in children in emergency department. Moderate asthma
152 Moderate asthma SpO2 92% No clinical features of severe asthma NB: If a patient has signs and symptoms across categories, always treat according to their most severe features agonist 2-10 puffs via
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis. Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine
Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine Asthma Defined National Asthma Education and Prevention
Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of